柳景华:CTO-PCI顽固性低血压原因及处理策略

2020-12-30 《门诊》杂志 门诊新视野

顽固性低血压是指重症休克患者经过输血、补液、升压药物等抗休克治疗后,血压仍难以回升,即休克低血管反应状态。

顽固性低血压是指重症休克患者经过输血、补液、升压药物等抗休克治疗后,血压仍难以回升,即休克低血管反应状态。在CTO-PCI中,顽固性低血压是临床棘手并发症之一,常与术中操作不当相关,如处理不及时患者易出现机体血容量不足、心脏射血量下降,增加心肌缺血和梗死面积,严重时出现心源性休克危及患者的生命安全。因此,积极预防并妥善处理CTO开通中的低血压及休克是每一位介入医生必备的临床能力。

CTO-PCI顽固性低血压之原因分析

CTO-PCI术后低血压的主要症状为面色苍白、恶心呕吐、大汗、心动过缓,严重时可出现意识状态的改变,持续时间较长且难以纠正的低血压将继发为休克乃至危及生命,主要病因如下:

硝酸酯类等血管扩张剂过量引起的血管张力减低;

局部血肿压迫导致血管的迷走反射亢进;

非冠脉部位出血,如穿刺或导丝损伤股动脉、腹腔动脉;

供血血管的缺血,进而引起的急性左心衰心律失常心肌梗死导致血流动学的崩溃;

心脏压塞、冠脉闭塞、冠脉夹层、冠脉痉挛无复流、支架内血栓形成等;

过敏反应如造影剂、麻醉药物、肝素等过敏并伴有过敏表现;

再灌注损伤,即缺血组织恢复血流灌注后,再灌注区心肌组织损伤进一步加重的现象,多伴有再灌注心律失常。

除此之外,应用于CTO-PCI术中的Guiding系统引发的主动脉瓣反流(AR)是常见原因之一,如Amplatz Guide导管常推挤主动脉瓣尖端以致严重反流的发生,进而引发顽固性的低血压。因此,CTO开通中发生低血压或休克的血流动力学不良情况时,应积极探求病因,以尽快对症处理以防危险事件的发生。

CTO-PCI顽固性低血压之PMCS

在积极处理低血压病因之下,血流动力学的支持器械(PMCS)(图1)为CTO-PCI术中顽固性低血压提供血流动力学支持亦十分关键;在临床操作中,为高危CTO-PCI患者术前预备IABP/ECMO等器械,可及时应对术中可能发生的低血压、休克,防止患者病情恶化。

在患者具备临床危险因素如合并严重肺动脉疾病、肾功能不全、左心室功能不全,或者解剖结构困难的CTO、合并多支血管等高危CTO病变的情况下,可积极采取血流动力学的机械支持策略。目前临床应用较广的IABP、Impella、TandemHeart、VA-ECMO等四种器械在功能性方面各有优劣之处,在临床实际中需结合患者病情特点进行选择(图2)。

图1.各类血流动力学机械支持(PMCS)

图2.PMCS的选择适应症

CTO-PCI顽固性低血压之病例分享

柳景华教授指出,在CTO开通的PCI手术中发生低血压或休克往往与术前评估与术中操作细节不到位相关,并结合自身经验分享了两例经典病案。

CASE1. 患者男性,78岁,因“胸痛10年,加重1月”入院;2016年因前降支闭塞曾于外院尝试CTO-PCI开通,但以失败告终。临床诊断为:急性心绞痛,LVEF 54%,心肌酶正常;CAG可见右冠远端CTO病变,LAD闭塞段较短有侧支形成。评估患者PCI风险因素后,考虑优先通过逆向导丝技术,同时预先准备IABP/ECMO的血流动力学支持措施以保护左冠功能。PCI过程中全程监测血压、心率,左冠回旋支置入Guiding后,出现患者血压逐步下降的状况,但未发现心包或动脉血管的穿刺损伤,遂予以多巴胺10 mg静脉注射,并维持多巴胺持续静脉输液。此时可见原供应LAD的侧支血管发生闭塞,患者表现出呵欠、出冷汗等症状,随即发生室颤,遂立即采取IABP/ECMO的支持策略,并终止CTO-PCI手术,改行CABG策略。外科手术成功,术后患者血运重建良好。

术前患者LVEF为54%,处于正常范围但偏低水平,风险评估中高估了患者的心脏承受能力,尽管众多侧支为LAD维持了血运,但由于侧支血管较为纤细,术中由于外部器械的刺激,一旦发生侧支血管的闭塞极有可能导致左冠缺血,进而引发低血压、休克。

CASE2. 患者男性,55岁,因“胸痛2年,加重1月”入院,2017年曾行PCI于LAD、LCX各置入支架一枚;2019年复发胸痛,于RCA、LCX各置入支架2枚。诊断:非典型心绞痛,高脂血症,LVEF 60%,肌钙蛋白0.23 ng/ml。PCI过程中,LCX开通顺利,但在术后半小时内患者出现严重的胸痛和血压下降,随即发生心脏骤停,遂停止手术进行抢救。在IABP/ECMO和大量多巴胺的支持下,患者恢复了血压,收缩压达110 mmHg,但LVEF降至20%。4天后患者循环恢复,血压、心律维持良好,但仍处于意识昏迷状态,因此拒绝CABG,考虑在IABP/ECMO支持下再行CTO的开通。

患者由于两次PCI手术病史,考虑支架内血栓的形成,极大增加了此次CTO-PCI的难度,而在此类高危患者进行手术之前,术者应注意患者全身情况、CTO及合并症,同时对整个PCI团队水平进行综合评估,否则很难达到预期的效果。

总 结

CTO有着冠脉介入领域“最后待以攻克的堡垒”之称,是冠脉介入医生的终极挑战。近年来随着PCI技术和器械的飞速进步,大量病例的积累下对CTO-PCI认知的不断深入,广大介入专家再次将目光聚焦于疾病本身,给予CTO-PCI的临床适应证、并发症、以及患者预后等更多的重视。“细节决定成败”,即使是稍许疏忽都有可能导致手术失败,甚至带来并发症,而顽固性低血压则是冠脉CTO术后的严重并发症,严重时出现心源性休克甚至威胁患者生命。目前,积极应用血流动力学机械支持是应对术中顽固性高血压乃至休克的可行策略,值得临床进一步发展应用。

讲者 首都医科大学附属北京安贞医院 柳景华教授

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862794, encodeId=3bf01862e94d2, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Jun 08 15:49:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632910, encodeId=17da163291028, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Wed Nov 24 19:49:36 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009598, encodeId=08422009598a9, content=<a href='/topic/show?id=434e42463ec' target=_blank style='color:#2F92EE;'>#处理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42463, encryptionId=434e42463ec, topicName=处理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Feb 16 03:49:36 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367413, encodeId=1302136e41375, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 01 08:49:36 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912268, encodeId=1de191226840, content=近年来随着PCI技术和器械的飞速进步,大量病例的积累下对CTO-PCI认知的不断深入,广大介入专家再次将目光聚焦于疾病本身,给予CTO-PCI的临床适应证、并发症、以及患者预后等更多的重视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 30 18:31:50 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
    2021-06-08 gao_jian4217
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862794, encodeId=3bf01862e94d2, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Jun 08 15:49:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632910, encodeId=17da163291028, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Wed Nov 24 19:49:36 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009598, encodeId=08422009598a9, content=<a href='/topic/show?id=434e42463ec' target=_blank style='color:#2F92EE;'>#处理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42463, encryptionId=434e42463ec, topicName=处理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Feb 16 03:49:36 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367413, encodeId=1302136e41375, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 01 08:49:36 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912268, encodeId=1de191226840, content=近年来随着PCI技术和器械的飞速进步,大量病例的积累下对CTO-PCI认知的不断深入,广大介入专家再次将目光聚焦于疾病本身,给予CTO-PCI的临床适应证、并发症、以及患者预后等更多的重视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 30 18:31:50 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862794, encodeId=3bf01862e94d2, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Jun 08 15:49:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632910, encodeId=17da163291028, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Wed Nov 24 19:49:36 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009598, encodeId=08422009598a9, content=<a href='/topic/show?id=434e42463ec' target=_blank style='color:#2F92EE;'>#处理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42463, encryptionId=434e42463ec, topicName=处理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Feb 16 03:49:36 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367413, encodeId=1302136e41375, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 01 08:49:36 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912268, encodeId=1de191226840, content=近年来随着PCI技术和器械的飞速进步,大量病例的积累下对CTO-PCI认知的不断深入,广大介入专家再次将目光聚焦于疾病本身,给予CTO-PCI的临床适应证、并发症、以及患者预后等更多的重视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 30 18:31:50 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1862794, encodeId=3bf01862e94d2, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Jun 08 15:49:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632910, encodeId=17da163291028, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Wed Nov 24 19:49:36 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009598, encodeId=08422009598a9, content=<a href='/topic/show?id=434e42463ec' target=_blank style='color:#2F92EE;'>#处理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42463, encryptionId=434e42463ec, topicName=处理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Feb 16 03:49:36 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367413, encodeId=1302136e41375, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 01 08:49:36 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912268, encodeId=1de191226840, content=近年来随着PCI技术和器械的飞速进步,大量病例的积累下对CTO-PCI认知的不断深入,广大介入专家再次将目光聚焦于疾病本身,给予CTO-PCI的临床适应证、并发症、以及患者预后等更多的重视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 30 18:31:50 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1862794, encodeId=3bf01862e94d2, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Jun 08 15:49:36 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632910, encodeId=17da163291028, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Wed Nov 24 19:49:36 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009598, encodeId=08422009598a9, content=<a href='/topic/show?id=434e42463ec' target=_blank style='color:#2F92EE;'>#处理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42463, encryptionId=434e42463ec, topicName=处理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Feb 16 03:49:36 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367413, encodeId=1302136e41375, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jan 01 08:49:36 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912268, encodeId=1de191226840, content=近年来随着PCI技术和器械的飞速进步,大量病例的积累下对CTO-PCI认知的不断深入,广大介入专家再次将目光聚焦于疾病本身,给予CTO-PCI的临床适应证、并发症、以及患者预后等更多的重视。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 30 18:31:50 CST 2020, time=2020-12-30, status=1, ipAttribution=)]
    2020-12-30 rayms

    近年来随着PCI技术和器械的飞速进步,大量病例的积累下对CTO-PCI认知的不断深入,广大介入专家再次将目光聚焦于疾病本身,给予CTO-PCI的临床适应证、并发症、以及患者预后等更多的重视。

    0

相关资讯

JAMA:替卡格雷vs氯吡格雷对PCI后急性冠状动脉综合征患者净不良临床事件风险的影响

对于常规临床实践中接受PCI的ACS患者中,与氯吡格雷相比,接受替卡格雷治疗患者的12个月净不良临床事件风险无显著性差异

JAMA Intern Med:PCI策略与急性心肌梗死和心源性休克患者不良预后

近年来急性心肌梗死和心源性休克患者接受多血管经皮冠状动脉介入治疗的比例逐年增加,但相比于主要梗死血管PCI,多血管PCI后患者的不良预后率也显著增加

Lancet:新冠肺炎疫情对英国急性冠状动脉综合征患者入院治疗率的影响

研究发现,新冠肺炎疫情期间,英国急性冠状动脉综合征患者入院治疗人数大幅减少,虽然到2020年5月底,这一数字已部分逆转,但在此期间入院人数的减少可能导致院外患者死亡和心肌梗死并发症风险增加

EuroIntervention:肥胖悖论——BMI的适度增加与PCI后患者生存率的改善相关

本研究旨在评估接受经皮血管重建术的冠状动脉疾病患者的体重指数(BMI)与结局之间的关系。

JAMA Intern Med:PCI vs CABG对冠心病患者全因及特异性死亡率的影响

与接受冠状动脉旁路移植术的患者相比,接受经皮冠状动脉介入治疗术后5年,冠心病患者的全因、心脏性和非心脏性死亡风险均较高

Lancet:曲美他嗪对PCI后心绞痛患者预后的影响

心绞痛患者在成功接受经皮冠状动脉介入治疗后,服用曲美他嗪对心绞痛的复发或预后无显著改善作用